Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452628 | 0.92 | NOTUM (0.45) | NOTUMHSD11B1MAPTNPY5RSMN1; SMN2 | |
| SCHEMBL23380315 | 0.92 | MAPT (0.53) | NOTUMTRPV1MAPTNPY5RSMN1; SMN2 | |
| SCHEMBL18580977 | 0.89 | SLC6A4 (0.42) | NOTUMTRPV1NPY5RSMN1; SMN2ALDH1A1 | |
| SCHEMBL14691021 | 0.85 | NOTUM (0.71) | NOTUMHSD11B1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13420777 | 0.83 | NOTUM (0.72) | NOTUM | |
| SCHEMBL24435477 | 0.83 | NOTUM (0.69) | NOTUMMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL892980 | 0.83 | NOTUM (0.69) | NOTUMMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2552991 | 0.82 | NOTUM (0.51) | NOTUMHSD11B1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14322637 | 0.82 | NOTUM (0.56) | NOTUMTRPV1NPY5RPDK2 | |
| SCHEMBL25174416 | 0.81 | NOTUM (0.73) | NOTUMHSD11B1TRPV1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | NOTUM 831/4885HSD11B1 642/4885TRPV1 1016/4885 |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NOTUM 3885/4885HSD11B1 4278/4885TRPV1 1180/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | NOTUM 2359/4885HSD11B1 175/4885TRPV1 1315/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | NOTUM 2359/4885HSD11B1 175/4885TRPV1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.